Abstract:Background: T cell receptors (TCRs) recognize epitopes from intracellular and cell surface antigens, enabling targeting of diverse tumor antigen classes including overexpressed, differentiation, cancer-testis antigens, as well as those from driver mutations, frameshift mutations, splice variants, and human endogenous retroviral elements (HERV). Melanoma-associated antigens (MAGE) are highly expressed in various solid tumor types, including melanoma, non-small cell lung cancers (NSCLC), bladder, and head and neck cancers, representing promising targets for TCR-T therapy. However, discovering robust and specific MAGE-reactive TCRs remains challenging due to limited throughput of TCR screening methodologies, and the inherently low frequency of tumor-reactive T cells in tumor samples and peripheral blood. Methods: We employ a proprietary mass-cytometry-based multiplexed tetramer staining approach, TargetScape®, to screen and characterize CD8+ T cells in healthy donors and patients' samples. Our screening panels contain multiple peptides for MAGE family antigens including A1, C2, and A10. Subsequent single cell sequencing or single cell PCR (scPCR) of identified tumor antigen-specific T cells with high sensitivity enables comprehensive analysis of T cell phenotype, transcriptome, TCR specificity, and paired TCR sequence. TCRs identified through this method are transduced for expression in Jurkat reporter cell lines and their reactivity to corresponding peptides is assessed. Selected TCR candidates are then transduced into primary T cells and evaluated for activation and effector function using a variety of cancer cell lines expressing the corresponding endogenous antigens. Specificity assessment is performed through alanine scans and identification of potential off-target peptides and screening for reactivity. Results: We utilized this approach to discover natural TCRs that target several MAGE family antigens. Through Jurkat reporter screening, we observed specific activation of multiple TCRs in the presence of antigen presenting cells and the peptide initially employed to identify the TCRs. Primary T-cells expressing promising TCR candidates exhibited killing activities and cytokine release when confronted with multiple solid tumor cell lines expressing endogenous levels of the MAGE antigen. Specificity assessment is currently in progress, with preliminary data indicating overall favorable specificity profiles for selected TCRs. Conclusions: Our Deep Immunomics platform enables us to detect, characterize, and validate TCR candidates against highly clinically relevant shared cancer antigens. Leveraging this platform, we identified various natural tumor specific TCRs exhibiting activities against a range of solid tumor cell lines expressing MAGE antigens. Promising candidates are currently undergoing in vivo efficacy studies. Citation Format: Juliana Velez Lujan, Hannah Fields, Kan Xing Wu, Yovita Purwanti, Emily Xin Zi Tang, Michael Cordeau, Kathleen Mendez, Melissa Wirawan, Michael Fehlings, Katja Fink, Zilei Liu, Daniel MacLeod. Discovery and development of T cell receptors targeting MAGE family antigens for adoptive T cell therapy against solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 13.

Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells

HER2 As a Promising Target for Cytotoxicity T Cells in Human Melanoma Therapy

Specific Inhibition Of Tumor Growth By T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen Ny-Eso-1/Lage-1

Soluble, High Affinity Tcrs Fused To Anti-Cd3 Redirect T Cells To Kill Cancer Cells Presenting Mage-A3 And Ny-Eso Antigens

Efficient lysis of CD44v7/8-presenting target cells by genetically engineered cytotoxic T-lymphocytes--a model for immunogene therapy of cervical cancer

Engineering a Dual Specificity γδ T-Cell Receptor for Cancer Immunotherapy

Abstract 5669: Establishment of a Human CD3ε Transgenic Mouse Model to Assess Anti-Tumor Efficacy of Human T-cell-redirecting Bispecific Antibodies

Abstract 13: Discovery and development of T cell receptors targeting MAGE family antigens for adoptive T cell therapy against solid tumors

Affibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor-3 Demonstrate Therapeutic Efficacy in Mice Bearing Low Expressing Xenografts

Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy

DC Targeting DNA Vaccines Induce Protective and Therapeutic Antitumor Immunity in Mice.

Abstract 6337: Tri-specific CD3 x HER2 x HER2 antibodies in 1:2 format recognizing two different epitopes on HER2 demonstrate selective activity on human cancer cells with high HER2 expression

Deciphering CD4+ T cell specificity using novel MHC–TCR chimeric receptors

Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties

In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts

Abstract 6342: Anti-tumor in vivo efficacy of different classes of anti-CLEC-1 myeloid checkpoint antibodies in monotherapy and in combination with chemotherapeutic agents

Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors

Abstract 22: Development and characterization of human tumor specific cytotoxic lymphocytes for preclinical drug development

A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells

Abstract 4056: Intratumoral delivery of autologous tumor antigen specific CD4 Th1 cells combined with dendritic cells eradicates HER2 mammary carcinoma

Harnessing the hERG1/β1 Integrin Complex via a Novel Bispecific Single-chain Antibody: An Effective Strategy against Solid Cancers